EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PMS2 c.2117del ( p.Lys706Serfs*19 ) is the Most Frequent Cancer‐Associated Founder Pathogenic Variant in the French‐Canadian Population of Quebec, Canada

Anne-Laure Chong iD, Alejandro Mejia-Garcia, Supriya Behl, Zaki El Haffaf, Sébastien Chénier, Bruno Maranda, Valérie Désilets, Sébastien Lévesque, Lysanne Castonguay, Anne-Marie Mes-Masson, Sylvie Giroux, François Rousseau und 4 weitere

Clinical Genetics · 2025

DOI: 10.1111/cge.14784 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Genetics, 2025. Verfasst von Anne-Laure Chong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Lady Davis Institute, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Mismatch Repair Endonuclease PMS2, Genetic Predisposition to Disease, Colorectal Neoplasms, Hereditary Nonpolyposis, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Research Institute of the McGill University Health Centre, Réseau de recherche sur le cancer (RRCancer).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We identified a PMS2 variant (NM_000535.7:c.2117del, p.Lys706Serfs*19) in 22 French‐Canadian (FC) families from Quebec with Lynch syndrome (LS; n = 21) or constitutional mismatch repair deficiency (CMMRD; n = 1). We aimed to (a) confirm its founder origin, (b) assess its allele frequency in the FC population, and (c) determine its contribution to the risk of developing various cancers in this population. We identified a haplotype common to all c.2117del alleles spanning 666 kb to 1.37 Mb, confirming the founder nature of the variant. In affected cases, the variant was found in 0 out of 821 breast cancer cases, 8 out of 693 (1.15%) endometrial cancer (EC) cases, and 1 out of 191 (0.52%) colorectal cancer (CRC) cases. In unaffected persons, the variant was identified in 22/6347 newborns (0.35%) and in 21/18129 FC CARTaGENE cohort participants (0.12%). Within this cohort, an excess of CRC (odds ratio: 10.7; 95% CI: 1.42–80.1; p value = 0.022), but not EC, was seen among heterozygotes for the PMS2 founder variant. Analysis of the variant in 24 subregions of Quebec showed over‐representation in 5 of them. Here, we report the most frequent genetic cause of mismatch repair deficiency syndromes identified thus far in the FC population of Quebec.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mismatch Repair Endonuclease PMS2Genetic Predisposition to DiseaseColorectal Neoplasms, Hereditary NonpolyposisNeoplastic Syndromes, HereditaryNeoplasmsHumansQuebecFemaleFounder EffectMaleHaplotypesGene FrequencyMiddle AgedAllelesAdultAged

Stichwörter der Autor:innen

French‐Canadian variantancestral recombination graphcolorectal cancerendometrial cancerimputation

Substanzen

Mismatch Repair Endonuclease PMS2PMS2 protein, human

Autor:innen und Institutionen

  • Lady Davis Institute, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
  • Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
  • Service de médecine génique, Centre Hospitalier de l'université de Montréal, Montreal, Quebec, Canada.
  • Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
  • Service de génétique médicale, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.
  • Service de génétique médicale, CHU de Québec-Université Laval, Quebec City, Quebec, Canada.

ORCID-Profile: Anne-Laure Chong, William D Foulkes

Förderung

  • CIHR
  • Research Institute of the McGill University Health Centre
  • Réseau de recherche sur le cancer (RRCancer)
  • FRQS Cancer Division
  • Merck Canada Inc.
  • Ministère de l'Économie, de l'Innovation et de l'Énergie du Québec
  • Canadian Institutes of Health Research
  • Institut de recherche, Centre universitaire de santé McGill

Zitieren

APA

Chong, A. L., Mejia-Garcia, A., Behl, S., El Haffaf, Z., Chénier, S., Maranda, B., Désilets, V., Lévesque, S., Castonguay, L., Mes-Masson, A. M., Giroux, S., Rousseau, F., Hamel, N., Chong, G., Gravel, S., & Foulkes, W. D. (2025). PMS2 c.2117del ( p.Lys706Serfs*19 ) is the Most Frequent Cancer‐Associated Founder Pathogenic Variant in the French‐Canadian Population of Quebec, Canada. Clinical Genetics. https://doi.org/10.1111/cge.14784

Vancouver

Chong AL, Mejia-Garcia A, Behl S, El Haffaf Z, Chénier S, Maranda B, et al. PMS2 c.2117del ( p.Lys706Serfs*19 ) is the Most Frequent Cancer‐Associated Founder Pathogenic Variant in the French‐Canadian Population of Quebec, Canada. Clinical Genetics. 2025. doi:10.1111/cge.14784

BibTeX
@article{Chong2025,
  author = {Chong, Anne-Laure and Mejia-Garcia, Alejandro and Behl, Supriya and El Haffaf, Zaki and Chénier, Sébastien and Maranda, Bruno and Désilets, Valérie and Lévesque, Sébastien and Castonguay, Lysanne and Mes-Masson, Anne-Marie and Giroux, Sylvie and Rousseau, François and Hamel, Nancy and Chong, George and Gravel, Simon and Foulkes, William D},
  title = {PMS2 c.2117del ( p.Lys706Serfs*19 ) is the Most Frequent Cancer‐Associated Founder Pathogenic Variant in the French‐Canadian Population of Quebec, Canada},
  journal = {Clinical Genetics},
  year = {2025},
  doi = {10.1111/cge.14784}
}
Kostenlos starten →